BioCentury | Jul 10, 2018
Distillery Therapeutics

Cancer

...number of additional inhibitors in fusion-negative rhabdomyosarcoma cell lines identified Mekinist plus the IGF1R inhibitor BMS-754807...
...decreased tumor growth and increased survival compared with vehicle. Next steps include testing Mekinist and BMS-754807...
...and solid tumors and preclinical studies for acute lymphoblastic leukemia (ALL). Bristol-Myers Squibb Co. has BMS-754807...
BioCentury | Feb 19, 2015
Distillery Therapeutics

Therapeutics: Epidermal growth factor receptor (EGFR); insulin-like growth factor-2 (IGF-2); insulin-like growth factor-1 (IGF-1) receptor (IGF1R; CD221)

...In mouse xenografts of patient-derived colon cancer that over-expressed IGF-2, Erbitux plus the IGF1R inhibitor BMS-754807...
...KGaA market Erbitux cetuximab to treat colorectal cancer and other cancers. Bristol-Myers Squibb Co. has BMS-754807...
BioCentury | Dec 15, 2008
Strategy

BMS cancer pipeline

...receptor Prostate cancer Ph I BMS-690514 EGFR/VEGFR inhibitor EGF receptor; VEGF receptor Cancer Ph I BMS-754807...
Items per page:
1 - 3 of 3